Viking Therapeutics inventory (VKTX) has been on a tear this week after it introduced the part II scientific trial outcomes for a brand new experimental drug within the booming weight-loss trade.
On Tuesday, shares of Viking Therapeutics greater than doubled, hovering over 120% to $85 as Wall Avenue cheered the outcomes.
The inventory shed a few of its large positive aspects on Thursday, falling by 15% to $80 a share in afternoon buying and selling, after the California-based firm introduced a $550 million stock offering. Viking issued 6.47 million shares at $85 every and mentioned it’ll use the money to fund the event of its weight-loss therapies, together with a capsule model.
Viking Therapeutics inventory was already off to a powerful begin this 12 months, however this newest win considerably added to its trajectory, with shares up 322% for the reason that starting of the 12 months.
The injectable drug in query, named VK2735, was credited with serving to sufferers lose as much as 15% of their physique weight in simply 13 weeks — outcomes that analysts say might make Viking a prime goal for acquisition.
Wall Avenue seen the outcomes as a stunning success, provided that Viking solely anticipated weight reduction to happen at a variety of between 7% to eight%, the present price for present weight-loss drug standouts equivalent to Novo Nordisk’s (NVO) Ozempic and Wegovy and Eli Lilly’s (LLY) Mounjaro and Zepbound.
“What’s so spectacular about this information is that this compound really precipitated extra weight reduction than Eli Lilly’s [medication],” BTIG analyst Justin Zelin instructed Yahoo Finance Reside. “So that they [Lilly] noticed a few 7% weight reduction round this time level. And Viking really doubled that. They confirmed 15% across the identical time level of 13 weeks. And that is why traders are so impressed right here.”
Zelin mentioned that sufferers might doubtlessly lose as a lot as 25% to 30% of their physique weight after a 12 months on the drug.
Analysts at William Blair responded to the information by elevating their peak gross sales estimate for Viking to $14.4 billion within the US and $7.2 billion in Europe from earlier valuations of $10.1 billion and $3.6 billion, respectively. In addition they pegged the corporate’s truthful worth at $9.9 billion ($98.99 per share), which is up from their earlier valuation of $5.5 billion.
“In the end, we imagine that the worth of VK2735 will probably be maximized within the arms of an enormous pharma, which might greatest navigate the rebate/discount-driven reimbursement panorama,” the analysts wrote in a word following the outcomes.
Zelin agreed that Viking’s outcomes probably renewed curiosity in a possible takeover.
“There’s been plenty of hypothesis on M&A and this title,” Zelin mentioned. “Clearly, it’s a reputation that’s of curiosity to Massive Pharma gamers.”
“Look, the GLP franchises are doing over $4 billion 1 / 4 in gross sales,” he continued. “Tirzepatide is doing over $1 billion 1 / 4; so, this can be a high-interest area that pharma’s taking a look at. You possibly can think about that gamers like Pfizer –– who had an asset [they discontinued] — are paying shut consideration to the area at the moment.”
Click on right here for the newest inventory market information and in-depth evaluation, together with occasions that transfer shares
Learn the newest monetary and enterprise information from Yahoo Finance
